Four bispecific antibodies are now approved for relapsed or refractory multiple myeloma. They produce response rates of roughly 60 to 70 percent in heavily pretreated patients, and they are available off the shelf, without the manufacturing wait CAR T-cell therapy requires.
The constraint is not the drug. It is the first two weeks of taking it.
Every myeloma bispecific requires step-up dosing, an escalating schedule designed to reduce the risk of cytokine release syndrome and neurotoxicity, with close monitoring during that window. That requirement has concentrated the therapy at academic medical centers, and new consensus documents published this year are explicitly attempting to move it outward. A European Delphi consensus led by María-Victoria Mateos and colleagues, published in eJHaem, sets out a framework for outpatient step-up dosing and for transferring patients from academic hospitals to community centers.
For a patient in a rural county, the practical question is whether a treatment that exists is a treatment they can actually get to.
The Bottleneck Sits in the First Two Weeks
The startup phase drives everything. Bispecific antibodies redirect a patient's T cells against myeloma cells, and that immune activation can produce cytokine release syndrome, most often during the first doses. Managing it requires trained staff, clear escalation protocols, rapid access to tocilizumab, and a plan for what happens if a patient deteriorates at 2 a.m.
There is a second, less clinical barrier. All myeloma bispecifics carry Risk Evaluation and Mitigation Strategy requirements, a certification burden that does not apply to bispecific antibodies approved for lymphoma or lung cancer. Pharmacies and prescribing physicians must both complete the process and maintain it.
That distinction has consequences on the ground. At an AJMC stakeholder meeting held in Washington in November 2025, panelist Kevin Brigle described the situation bluntly, saying, "No one in our community is REMS certified for any of the myeloma bispecifics," even among practices willing to administer lymphoma bispecifics after step-up dosing.
Reimbursement compounds it. The staffing time and coordination that step-up dosing demands are not adequately covered by current payment structures, according to Lekan Ajayi, PharmD, chief operating officer of Highlands Oncology Group, speaking to AJMC in June 2026. A community practice can want to offer the therapy and still lose money doing it.
The result is a referral pattern that experts describe consistently. Academic centers perform step-up dosing, then hand patients back to local oncologists for ongoing maintenance. That works when a patient lives within reach of an academic center and has lodging, a reliable caregiver, and the ability to be away from home for the initiation period. It works less well otherwise.
Numbers Behind the Geographic Divide
Practice-pattern data give the gap some shape, though the picture is more mixed than the anecdotes suggest.
A retrospective analysis of records from the US Oncology Network, which supports more than 700 centers, was presented at the American Society of Hematology annual meeting in December 2025. Investigators examined patients treated between October 2022 and July 2025 and reported rapid uptake and steady growth in community settings. Of 751 patients identified, 405 received a bispecific antibody, and 346 clinically qualified based on prior lines of therapy. Uptake rose to 4.7 percent of patients initiating qualifying therapy in 2022.
Rural clinics accounted for 13.3 percent of the full study population and 16.3 percent of the bispecific group, compared with 9.8 percent of the non-bispecific group, which suggests rural patients within this particular network were not being systematically excluded.
Travel burden data from an adjacent setting are less encouraging. A separate ASH 2025 analysis of Medicare beneficiaries receiving bispecific antibodies for diffuse large B-cell lymphoma and follicular lymphoma found that rural patients traveled an additional 56 miles and roughly 54 minutes one way compared with urban patients, and those in counties without hospital oncology services traveled farther still. That study covered lymphoma rather than myeloma, so it indicates direction rather than a myeloma-specific measurement.
An earlier interprofessional consensus panel published in Blood Cancer Journal attributed disparities in CAR T-cell and bispecific therapy largely to limited availability outside high-volume centers.
Consensus Documents Are Not Trial Evidence
Three publications this cycle are attempting to close the gap, and it is worth being precise about what they are.
A global roadmap led by Alfred Garfall and Rahul Banerjee, published in Frontiers in Oncology, was developed through three clinician advisory workshops in the United States, Europe, and Latin America. Its authors noted that adoption outside academic centers "can be challenging due to a lack of physician experience" with these agents and the necessary infrastructure. The roadmap addresses multidisciplinary team composition, patient selection, step-up procedures, caregiver education, and adverse event monitoring.
The European Delphi consensus provides a structured framework for outpatient step-up dosing of BCMA-targeting bispecifics and for transition of care. Its authors state plainly that the recommendations rest on expert opinion rather than prospective clinical data, and describe the work as a foundation for future real-world validation.
Early real-world reports are small but suggestive. A single-institution community experience published in the Journal of Hematology Oncology Pharmacy in 2026 reported that although 40 percent of patients had cytokine release syndrome during step-up doses, all tolerated the final step-up dose without CRS or neurotoxicity, and none had a treatment-related hospitalization after moving to outpatient administration. That is one institution with a selected patient group; no evidence suggests any practice can replicate the result.
Patient selection is doing significant work in all of these frameworks. Candidates for outpatient initiation generally need low tumor burden, good performance status, controlled comorbidities, no active infection, a reliable caregiver, and proximity to a hospital. A patient who fails those criteria still requires an academic center, and those criteria correlate with the same social and geographic advantages that already predict better cancer outcomes.
Options for Patients Far from an Academic Center
Nothing in this reporting should prompt anyone to change or delay treatment. These are questions for an oncology team.
Patients with relapsed or refractory myeloma can ask their oncologist directly whether bispecific antibody therapy is an option for them, and if the local practice cannot administer it, whether a co-management arrangement is available in which an academic center handles step-up dosing and the local team resumes care afterward. Asking early matters, because these referrals take time to arrange and patients who wait until disease progression accelerates have fewer options.
Practical questions worth raising include how long the initiation period requires staying near the treating center, whether lodging assistance exists, and what caregiver presence is expected. Patients can also ask whether nearby practices have completed REMS certification, since that status changes.
On cost, all four manufacturers operate patient assistance programs, and cancer center financial navigators and social workers are the fastest route into them. The Patient Advocate Foundation and NeedyMeds assist with coverage appeals and travel-related expenses. Medicare beneficiaries should ask how the therapy is billed, since site of care affects out-of-pocket exposure.
What remains unknown is whether any of this shifts delivery patterns. As bispecifics move into earlier lines of therapy, some panelists at a May 2026 health equity meeting summarized by AJMC predicted community adoption would follow the pattern set by anti-CD38 antibodies, while others predicted access disparities would widen in the near term before narrowing. No prospective study has tested whether the new consensus frameworks improve safety or reach. MedicalDaily will follow the validation studies those documents call for.
Frequently Asked Questions
What are bispecific antibodies for myeloma? They are off-the-shelf immunotherapy drugs that bind both a myeloma cell target and a T cell, directing the immune system to attack the cancer. Four are FDA-approved for relapsed or refractory disease.
Why can't most community practices start them? Starting therapy requires step-up dosing with close monitoring for cytokine release syndrome and neurotoxicity, plus REMS certification that lymphoma and lung cancer bispecifics do not require.
Are rural patients being excluded? The picture is mixed. One community network analysis found rural patients represented a slightly higher share of bispecific recipients than non-recipients. A separate Medicare analysis in lymphoma found rural patients traveled about 56 additional miles each way.
What is co-management? An arrangement in which an academic center performs the initial step-up dosing and then transfers ongoing maintenance therapy back to a patient's local oncologist, with continued consultation available.
Do the new consensus documents change treatment guidelines? No. They are expert consensus frameworks based on clinician panels rather than prospective clinical trials, and their authors describe them as a foundation for future validation.
Who qualifies for outpatient initiation? Frameworks generally point to patients with low tumor burden, good performance status, controlled comorbidities, no active infection, a reliable caregiver, and access to a hospital.
What financial help exists? All four manufacturers run patient assistance programs. Cancer center financial navigators, the Patient Advocate Foundation, and NeedyMeds can help with coverage appeals and travel costs.
